Manorama Industries Limited

Food Processing #1/1Sub-sector: Specialty Fats and OilsQtr Score Rank 1 / 71 (Top 100 percentile)Growth Score Rank 1 / 68 (Top 100 percentile)

Industry Context

Industry Context is not ready yet for this company.

We have not generated company-specific industry context for this company yet.

Business Snapshot

06 Mar

About

Producer of cocoa butter equivalents and specialty fats derived from forest-sourced tree-borne seeds.

The company transforms underutilized natural resources like Sal seeds and Shea nuts into sustainable specialty fats and butters for the global chocolate, confectionery, cosmetics, and bakery industries through an integrated 'forest to fortune' model.

Revenue Breakdown

By Segment

Chocolate and Confectionery

Supply of cocoa butter equivalents and specialty fats for chocolate and candy production.

Cosmetics

Production of exotic plant-based butters and ingredients for personal care and beauty products.

Show more (1)

Bakery and HoReCa

Specialty fats and ingredients tailored for the bakery, hotel, restaurant, and cafe industries.

By Product / Service

Cocoa Butter Equivalents (CBE)

Fats derived from tree-borne seeds that mimic the properties of cocoa butter.

Refined and Fractionated Butters

Customized specialty fats and butters for diverse food and personal care applications.

Show more (1)

De-Oiled Cake (Cattle Feed)

A by-product of the seed extraction process used for animal nutrition.

Quarterly Score

↔ Trend: Stable
Insufficient data for trend analysis

Score trend

12 quarters

Latest 12 quarters, oldest to newest. Click a point to inspect that quarter.

Quarter

Q3 FY2026

LatestStrongly Bullish
Score
9.5

Quarter summary

  • The company sustained robust growth momentum, attributing it to an enhanced value-added product mix and optimized utilization of recently upgraded facilities.
  • A significant strategic capital expenditure plan of INR 460 crores was announced for both forward and backward integration, targeting long-term capacity and market leadership.

Rationale

  • Achieved exceptional revenue growth of 73.3% YoY in Q3 FY26 (INR 363 crores) and 81.3% YoY in 9M FY26 (INR 975 crores), primarily driven by ~65% volume growth and an enhanced mix of value-added products.
  • Upwardly revised FY26 revenue guidance by ~13% (from INR 1,150 crores to INR 1,300 crores), demonstrating strong confidence in sustained performance and market demand.

Latest quarter context.

Future Growth Prospects

8.9

Summary

Updated: 05 Mar 2026
  • Expanding fractionation capacity to 52,000 MTPA by FY26 through debottlenecking, enhancing throughput by 30%.
  • Committing INR 460 Crores capex over the next 2-3 years for new facilities: 75k MTPA for CBE alternatives, 75k MTPA for solvent fractionation (ESOS), 90k MTPA for refinery, and 90k MTPA processing in Burkina Faso.
  • Targeting a significant shift towards value-added product sales, aiming for 85%-90% contribution to total sales 'going forward'.

Top 3 Growth Catalysts

New Capacity Expansion & Debottlenecking

capacityImpact: revenue

Timeline

  • scale expansionFY24 · ppt

    Fractionation capacity increased from 15,000 TPA to 40,000 TPA.

    25,000 TPA added

  • ramp upQ3 FY26 · concall

    Debottlenecking existing capacity to 52,000 MTPA by end of FY26.

    Existing capacity increasing by 12,000 MTPA

Show full timeline (5)
  • commissioningFY28 · concall

    All new production capacity (~460 Cr capex projects) expected to be commenced.

    Full new capex expected online

  • commissioningJuly 2024 · ppt

    New 25,000 MTPA fractionation facility commercialized, taking total to 40,000 MTPA.

    New facility commercialized

  • capex startNext 2-3 years · concall

    INR 460 Cr capex for 75k MTPA CBA, 75k MTPA solvent fractionation, 90k MTPA refinery, 90k MTPA Burkina Faso processing.

    Significant new facilities planned

Product Diversification & Value-Added Mix Shift (CBA/ESOS)

productImpact: margin

Timeline

  • unknownQ3 FY26 · concall

    New fractionation capacity will be used for ESOS and HPMF, blended with existing stearin to make value-enhanced products.

    Shift to value-enhanced ESOS products

  • first mention2024-25 · annual_report

    Launched new value-added products.

    New products introduced

Show full timeline (4)
  • unknownNext 2-3 years · concall

    Setting up 75k MTPA CBA manufacturing facility and 75k MTPA new Solvent Fractionation facility for ESOS.

    New dedicated facilities for value-added products

  • quantified guidanceGoing forward · concall

    Aim to increase value-added product sales to 85%-90%.

    Higher proportion of value-added sales expected

Global Geographical Expansion & Backward Integration (Africa & Latin America)

geoImpact: revenue

Timeline

  • ramp upQ3 FY26 · concall

    First commercial production batch at Dekel (Brazil partnership) accomplished, trial samples delivered.

    Initial production in Brazil

  • commissioningNovember 2025 · ppt

    Production expected to commence in Brazil partnership.

    Brazil manufacturing commencement

Show full timeline (4)
  • first mention2024-25 · annual_report

    Established 8 new subsidiaries globally across critical geographies.

    New global subsidiaries formed

  • capex startNext 2-3 years · concall

    Backward integration to processing factory in Burkina Faso (90k MTPA).

    Processing facility planned in Africa

See more about future growth

Open detailed variant perception and scenario analysis.

Open

Variant perception

Non-consensus view
Consensus

The market acknowledges Manorama’s robust growth and capacity expansion plans but may be largely factoring in the guided FY26 revenue and current margin stability, without fully discounting the acceleration from upcoming large-scale project

Upside
  • Faster than guided ramp-up of 460 Cr capex projects driving earlier revenue and margin realization.
Show more (2)
  • New value-added products (CBA/ESOS) achieve higher penetration and pricing power than currently de-risked.
  • Operational synergies from global expansions and backward integration result in significant cost reductions and improved working capital beyond current targets.
Downside
  • Execution delays or cost overruns in the INR 460 Cr capex projects, pushing out benefits beyond the 2-year horizon.
Show more (2)
  • Intensified competition or lower demand for specialty fats/butters could temper new product revenue growth.
  • Inability to fully integrate new global subsidiaries or achieve projected efficiencies from backward integration.
base case90% conf
Growth: 30%

Quick takeaway

Capacity expansion to 52,000 MTPA by FY26 end

Risk watch: Delays in new capacity commissioning beyond FY26

Show details (2 drivers, 2 risks)

Drivers

  • Capacity expansion to 52,000 MTPA by FY26 end
  • Continued shift to 75-85% value-added product sales

Risks

  • Delays in new capacity commissioning beyond FY26
  • Increased competition in new geographies
upside case70% conf
Growth: >35%

Quick takeaway

Accelerated ramp-up and full utilization of new facilities (CBA, Solvent Fractionation, Refinery)

Risk watch: Potential for unexpected operational issues during new plant stabilization

Show details (2 drivers, 2 risks)

Drivers

  • Accelerated ramp-up and full utilization of new facilities (CBA, Solvent Fractionation, Refinery)
  • Higher-than-expected demand for ESOS and other value-enhanced products

Risks

  • Potential for unexpected operational issues during new plant stabilization
  • Market volatility impacting new product adoption
downside case60% conf
Growth: <25%

Quick takeaway

Increased cost efficiencies from backward integration in Africa

Risk watch: Execution risks in commissioning new plants

Show details (2 drivers, 2 risks)

Drivers

  • Increased cost efficiencies from backward integration in Africa
  • Faster customer acquisition in Latin America

Risks

  • Execution risks in commissioning new plants
  • Higher raw material price volatility affecting new product margins

Guidance History

Not ready

Guidance History is not ready yet for this company.

We have not tracked meaningful management guidance for this company yet.

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...
Submit Request